FiteBac® dental video library
FiteBac Presents in Germany at International Dental Show

U.S.-Based FiteBac Presents in Germany for First Time at International Dental Show, IDS2021, to Feature New Antimicrobial Additives for Dental Restorative MaterialsSummary: FiteBac will be a new, featured presenter at the world’s largest dental conference, IDS 2021,...

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Clinical trial

Quaternary Ammonium Methacryloxy Silicate-containing Acrylic Resin

One of the major challenges in orthodontic treatment is long-term stability. Because removable retainers are worn for at least 1 year, bacteria and fungi may accumulate on the retainers in the form of multi-species plaque biofilms. This may result in increased incidence of proximal dental caries or oral candida infection. Thus, incorporation of antimicrobial activity in orthodontic acrylic resin to achieve plaque biofilm reduction is highly desirable. An antimicrobial and antifungal quaternary ammonium methacryloxy silicate (QAMS) molecule has been synthesized by sol-gel reaction and incorporated into orthodontic acrylic resin.

Read more

The QAMS-copolymerized acrylic resin demonstrated contact-killing properties against single-species biofilms in previous in vitro studies and has received US FDA 510(K) clearance for marketing.

The objective of the present randomized clinical trial is to determine the in vivo antimicrobial efficacy of the QAMS-containing orthodontic acrylic by using removable retainers that are worn by recruited subjects to create 48-hour multi-species plaque biofilms. The null hypothesis tested is that there is no difference in the antimicrobial activities between QAMS-free and QAMS-containing orthodontic acrylic resin on oral biofilms grown in vivo in human subjects.